Health Care Resource Use at End of Life in Patients with Advanced Lung Cancer
Source abstract
Abstract
We aimed to study differences in the use of health care resources in relation to time before death in patients with advanced lung cancer who either received systemic anti-cancer treatment (SACT) or were ineligible for SACT. A retrospective cohort of lung cancer patients (N = 778) diagnosed with advanced disease at North Estonia Medical Centre from 2015–2017 was linked to population-based health care data. We calculated a composite measure of cumulative resource use, comprised from the following: outpatient care, emergency department (ED) visit, inpatient care, admission to intensive care unit, nursing care and prescriptions. Costs were highest in patients who received SACT in the last month before death and decreased in parallel with the time elapsed from the last SACT. Only 20% of SACT patients received nursing care in the final month of life. The no-SACT patients had less time covered by health care services per month, and large differences were seen in the type of service received by the study groups. The largest contributor of health care costs at end of life was acute inpatient care, including approximately 10% of patients who died on the same day as or day following the emergency department visit. These results demonstrate the low nursing care and hospice utilization rates in Estonia.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Palliative Care and End-of-Life Issues · Cancer survivorship and care · Economic and Financial Impacts of Cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemotherapy, Clinic of Oncology and Haematology, North Estonia Medical Centre, 13419 Tallinn, Estonia
Institute of Family Medicine and Public Health, University of Tartu, 50411 Tartu, Estonia
North Estonia Medical Centre, 13419 Tallinn, Estonia
References (20)
Show source-provided references
1. Global Burden of Disease Cancer Collaboration. The Global Burden of Cancer 201310.1001/jamaoncol.2015.0735 ↗
2. Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer10.1093/jnci/djz212 ↗
3. Jeon, S.M., Kwon, J.-W., Choi, S.H., and Park, H.-Y. (2019). Economic burden of lung cancer: A retrospective cohort study in South Korea, 2002–2015. PLoS ONE, 14.10.1371/journal.pone.0212878 ↗
4. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries10.3322/caac.21492 ↗
5. Economic burden of cancer across the European Union: A population-based cost analysis10.1016/S1470-2045(13)70442-X ↗
6. Health care costs for patients with cancer at the end of life10.1200/JOP.2011.000469 ↗
7. Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare10.1002/cam4.1896 ↗
8. One Step Forward, Two Steps Back: Trends in Aggressive Inpatient Care at the End of Life for Patients With Stage IV Lung Cancer10.1200/JOP.18.00515 ↗
9. Patterns of survival and surgical treatment in lung cancer patients in Estonia by histologic type and stage, 1996–201610.1080/0284186X.2019.1637539 ↗
10. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries10.1016/S0140-6736(17)33326-3 ↗
11. Oselin, K., Pisarev, H., Ilau, K., and Kiivet, R.-A. (2021). Intensity of end-of-life health care and mortality after systemic anti-cancer treatment in patients with advanced lung cancer. BMC Cancer, 21.10.1186/s12885-021-07992-5 ↗
12. Bone and brain metastasis in lung cancer: Recent advances in therapeutic strategies10.1177/1758834014521110 ↗
13. Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer10.1056/NEJMoa1000678 ↗
14. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer10.1200/JCO.2011.35.7996 ↗
15. Where do people die? An international comparison of the percentage of deaths occurring in hospital and residential aged care settings in 45 populations, using published and available statistics10.1007/s00038-012-0394-5 ↗
16. Medical costs of Japanese lung cancer patients during end-of-life care10.1093/jjco/hyaa259 ↗
17. An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data10.1177/0269216315596505 ↗
18. Secondary-care costs associated with lung cancer diagnosed at emergency hospitalisation in the United Kingdom10.1136/thoraxjnl-2016-209616 ↗
19. Factors affecting hospital costs in lung cancer patients in the United Kingdom10.1016/j.lungcan.2016.04.009 ↗
20. Voda, A.I., and Bostan, I. (2018). Public Health Care Financing and the Costs of Cancer Care: A Cross-National Analysis. Cancers, 10.10.3390/cancers10040117 ↗